MBMV invests in international bio-tech startup Arcensus from Rostock


Leveraging Whole Genome Sequencing (WGS), Arcensus GmbH, based in Rostock, enables the early detection of both rare and common disorders such as cancer or heart diseases. This allows for the initiation of preventive and personalized treatments at the earliest stages. As Arcensus marks its one-year anniversary, it is securing fresh capital for further expansion. In the current investment series, Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern (MBMV) is investing a single-digit million to support expansion into the US and GCC regions.

For MBMV, this investment holds special significance, as Managing Director Dr. Thomas Drews notes, “With Arcensus, we are investing in a highly experienced and well-known team, utilizing a technology that, in this precise combination, holds the potential to significantly contribute to disease prevention and the cure of rare diseases.” He adds, “We are proud that a local company from Rostock is positioned as a figurehead in the international biotech scene.”

Arcensus builds on their extensive experience in Whole Genome Sequencing technology and integrating game-changing artificial intelligence (AI) for deep interpretation of DNA information. This approach aims to provide customers with profound insights into inherited diseases andmedical insights to understand and improve their health, achieve lasting quality of life and save lives.”

Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern (MBMV) is a regional entity dedicated to supporting small and medium-sized enterprises (SMEs) through capital provision for economic projects. The organization aids SMEs in stabilizing or expanding their market position, with a particular focus on innovative companies with a supra-regional or international orientation.

Share this page: